The ability of 5-hydroxytryptamine (5-HT) to augment contractions evoked by other agents (and vice versa) in vascular smooth muscle has been studied for many years (see [ 1, 21 for reviews). The abundance of the data available contrasts starkly with the lack of knowledge of the mechanisms underlying such amplification phenomena. Our own interest in 5-HT stems from not only the proposed involvement of this amine in cardiovascular disease involving platelet aggregation, but also from the more recent knowledge that both 5-HT, and 5-HT, receptors mediate contraction of vascular smooth muscle. Thus, there is a multitude of possible interactions between the various factors released from aggregating platelets. We have examined the interactions between the plateletderived products 5-HT and thromboxane A, (TxA,), which are found in elevated concentrations in the plasma of patients with cardiovascular disease [3, 41. Interactions between 5-HT and TxA, were studied in the rabbit femoral artery [5, 61. Briefly, vascular ring segments were suspended in organ baths filled with Krebs' saline for recording isometric force changes. As this tissue possesses both 5-HT, and 5-HT, receptors, one of these has to be eliminated to examine exclusively the interaction between 5-HT, or 5-HT, receptors and TxA, receptors. 5-HT, receptors were isolated by including the 5-HT2 receptor antagonist spiperone (0.3 p M ) in the saline. 5-HT, receptors were isolated by irreversibly alkylating 5-HT, receptors using There was no significant increase in the maximum response to a-Me-5-HT at any concentration of U46619. These data can be illustrated further in the form of histograms showing the effects of different concentrations of a-Me-5-HT and U466 19, alone and in combination (Figure lb) . This shows that, at lower concentrations only, the effect of these two agents when applied in combination is greater than the simple sum of their individual effects.
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The interaction between agonists acting at 5-HT, and at TxA, receptors are consistent with the expectations of threshold synergy [5] . A theoretical model of threshold synergy [7] The model can be used to predict the resultant of interactions between agonists if one assumes that the steepness of agonist concentration-effect curves reflects the geometry of the common transducer process [8, 91 . Thus, mutual threshold synergy is predicted between agonists having steep concentration-effect curves and whose transduction pathways overlap. In the rabbit femoral artery, the agonists U46619, a-Me-5-HT and angiotensin I1 each induce contraction and have steep concentration-effect curves; the logistic curve slope parameters are 2.1, 1.8 and 1.6 respectively. It is not unreasonable to assume that the transduction pathways for these agonists merge since the activation of their receptors (5-HT,, TxA, and angiotensin 11,) in vascular smooth muscle is apparently in keeping with their second messenger pathways in other cell types, that is, they are coupled to the hydrolysis of inositol phospholipids [ 10-151. It is not surprising, therefore, that threshold synergy, which is predicted for the interaction between any two of these agonists in rabbit femoral artery, is upheld (S. J. MacLennan, M. I,. Bolofo and G. R.
Martin, unpublished work).
The merits of one model of threshold synergy have been described. As it is a model only, it is open to modification and development [7] , and it is unreasonable to believe that it will predict all interactions between agonists. Indeed, the interaction between 5-HT and noradrenaline in the rabbit aorta cannot be explained in terms of this model [ 16, 171. It has been proposed that multiple transduction pathways for noradrenaline in this tissue may underlie this complex interaction [7] .
Interactions between 5-HT, and TxA, receptor-mediated responses (Figure 2 b ) or U46619 in a manner similar to that described for 5-HT, responses, thus suggesting that this type of amplification is not related to a receptor type, but that it is a consequence of post-receptor interactions. In contrast to the interaction between 5-HT, and (Figure 3) . Clearly, it is difficult to envisage a final common process for these tranduction pathways and thus to be in accord with the general scheme of threshold synergy. The problem then is to try to resolve how the inhibition of cyclic AMP may be linked to contraction of smooth muscle. A major obstacle to understanding this problem is the relative lack of data about the second messenger pathways, and the cross-talk between them, in vascular smooth muscle.
Exposure of 5-HT, receptors in rabbit femoral artery is not unique. In several other blood vessels (from different species, including human), 5-HT, receptor-mediated contraction is either revealed or greatly enhanced by other agents [6, . Indeed, this phenomenon is not confined to 5-HT, receptors. In rabbit femoral artery, NPY,-mediated contraction can be amplified by angiotensin I1 and U46619 (see above); a,-adrenergic-mediated contractions of rabbit saphenous artery [26] and rat caudal artery [27] are exposed using angiotensin I1 and vasopressin. The features shared by these receptor systems that can T be uncovered (5-HT,, NPY,, a,) are that each is purportedly coupled negatively to adenylate cyclase (this study) [18, 19, [28] [29] [30] and that the agonists used to reveal the receptor (the priming agent) activate receptor systems that are believed to be coupled to phosphatidylinositol 4,s-bisphosphate (PIP,) hydrolysis (TxA,, angiotensin II,, a,).
The contractile state of smooth muscle is regulated ultimately by the free concentration of intracellular calcium [CaZ+] ,; and therefore any mechanism regulating this will influence smooth muscle contraction. The well-documented effect of cyclic AMP on [Ca2+], suggests one possible mechanism to account for the contraction via receptors coupled negatively to adenylate cyclase. Elevation of cyclic AMP leads in general to a decrease in [18, 191 (which does not require 'priming') in terms of this theory would require that there were higher basal levels both of cyclic AMP and of PIP, turnover (relative to the rabbit femoral artery, which requires priming). In this scenario, the inhibition of cyclic AMP would allow basal PIP, hydrolysis to induce contraction.
The second potential mechanism that could account for receptor-mediated contraction via the inhibition of cyclic AMP involves the role of this second messenger in inositol phospholipid hydrolysis. Accumulating evidence from the last five years shows conclusively that agents that elevate the concentration of cyclic AMP (/?-adrenoceptor agonists, analogues of cyclic AMP, phosphodiesterase inhibitors) can also lead to a reduced hydrolysis of phospholipids in smooth muscle [33- These first two theories may suggest that there is a simple balance between the factors promoting (Ca2+ /inositol 1,4,5-trisphosphate/diacylglycerol) and opposing (cyclic AMP) smooth muscle cell contraction. Provisional evidence that does not support this rather simple 'balance' theory is provided here (Figure Zu) . The amplitude of 5-HT,-mediated contraction (after subtraction of the U46619-induced effect) is greater in the presence of the lowest concentrations of U46619 (1 nM) than in control tissues, but the midpoint location is unchanged. At higher concentrations of U46619 (Alo and A3,J there was a further increase in the maximum response accompanied by a progressively leftward shift of the concentration-effect curve. These data are compatible with a simple efficacy change for 5-HT, and are not consistent with there being a simple balance between contractile and relaxatory forces. If this were the case, it would not be expected that the amplitude of 5-HT, receptor-mediated effects (that is, the efficacy of 5-HT) be dependent on the concentration of priming agent. The data point therefore to a rather more complex interaction of cyclic AMP with the pharmacomechanical coupling process.
A third way in which cyclic AMP can influence smooth muscle cell contractility is by regulating the sensitivity of the contractile proteins. The original work of Adelstein and colleagues [41, 421 found that cyclic-AMP-dependent kinase phosphorylated myosin light chain kinase thus reducing (via a lower affinity for Ca2+ calmodulin) the phosphorylation rate of myosin light chain and hence leading to smooth muscle relaxation. More recent work has questioned the physiological importance of the phosphorylation of myosin light chain kinase as the key role in regulating the contractile elements . The elegant studies of Nishimura and van Hreemen [43] using a-toxin-permeabilized rat mesenteric arteries, to permit the entry of molecules such as cyclic AMP into the cytosol, have shown that exogenous cyclic AMP and cyclic GMP lower the Ca2+ sensitivity of the contractile elements. Whatever the mode of action of cyclic AMP, its regulatory role on the contractile elements of smooth muscle suggests a further mechanism to account for contraction via receptors coupled negatively to adenylate cyclase.
Each of these three theories requires that the inhibition of the basal amounts of cyclic AMP can account for contraction after activation of receptors such as 5-HT,, NPY, and a2. Clearly it will be necessary to determine if this is the case. If however, the priming agent increased the levels of cyclic inositol phospholipid hydrolysis this could lead to an apparent increase in the efficacy of 5-HT, receptor activation.
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Conclusions
There is clearly an enormous amount still to learn about the second messenger pathways in smooth muscle and how they interact. Such knowledge will be central to understanding the mechanism(s) that allow the exposure or uncovering of receptors. It will be of interest to determine if this phenomenon is observed in other receptor systems in vascular smooth muscle, as well as those described here, and to elucidate the physiological role of these otherwise silent receptors.
